Navigation Links
Korean Stem Cells Allow Artist to Paint Again
Date:3/31/2009

ROCKVILLE, Md., March 31 /PRNewswire/ -- John Lawson Cullison, Jr., an artist known for his work in the genre of visionary realism or "new age art," lost his ability to paint due to the effects of arthritis. This incurable condition is due to the degeneration in cartilage tissue and symptoms include: pain, tenderness in the joints, stiffness, loss of flexibility, bone spurs and severe swelling. Pain management and joint replacement surgery are the typical means to treating this condition. Cullison was taking prescription pain medication for over 15 years when he finally decided to seek treatment that was unavailable in the United States.

RNL Bio, a South Korean adult stem cell therapy company, developed a method to take one's own stem cells from fat tissue and make identical copies that have no genetic modifications and no cancer risks so that high doses of stem cells can be administered back into the body. The stem cells that come from fat tissue can easily form new tissues. Given that characteristic, the stem cells have the capacity to treat any tissue degenerative disease which includes, Parkinson's Disease, Spinal Cord Injury, Renal Failure, among many. When Cullison heard of the treatment, he sent a small fat sample to RNL Bio, where the cells would be manufactured under the strictest safety and quality conditions.

February 2009, Cullison made the trip to Seoul, South Korea where he was escorted by RNL staff to The Sunrise Regenerative Medical Center, their stem cell hospital in Yanji, China to receive intravenous and local injections of his own stem cells. When asked about his decision to seek this new and developing treatment, he said, "I had more faith in that [the fact that RNL was using my own stem cells] because I knew that I would be receiving the material that genetically was supposed to be in me.".

A week after his injection, Cullison began to see small improvements and after two weeks, he no longer needed his cane to walk. He noticed that his joints were feeling better, his vision was improving to the point that his glasses were outdated, his eyes were getting bluer (eye pigmentation is often an indicator of good health) and his legs were getting stronger. "This is major improvement and it's only been 2 weeks! Six months from now, I'll be doing back-flips!" Only three weeks post treatment, Cullison reported that he was no longer taking any medication and back to painting his pictures.

President and CEO of RNL Bio, Dr. Jeong Chan Ra said, "John Cullison arrived in Korea as an old man. He is returning to his home, an adolescent". After witnessing the remarkable improvement of Cullison as well as patients being treated with RNL stem cells, Ra is committed to making RNL stem cell therapy an accessible and affordable treatment, globally.

About RNL Bio

RNL Bio is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis. RNL is a publically traded company on the Korean Stock Exchange (Code 003190) and plans to expand its operations throughout the world. For questions regarding the press conference or receiving stem cell therapy, please contact, Jin Han Hong, at hongjh@rnl.co.kr


'/>"/>
SOURCE RNL Bio
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chronic gastrointestinal symptoms in Korean population
2. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
3. CHRI Gets Great Progress on the Korean Herb Market
4. China Medical Technologies Announces Receipt of Korean FDA Approval for its HIFU System
5. Eye Cells Believed to Be Retinal Stem Cells Are Misidentified
6. After heart attack, bone marrow stem cells increase blood flow within heart
7. Scientists Capture HIV Transfer Among T-Cells on Video
8. Study Links Sugar Production in Yeast Cells to Longevity
9. Physician Group Opposes FDA's Position on Adult Stem Cells
10. TV crime drama compound highlights immune cells misdeeds
11. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Irvine, CA (PRWEB) , ... March 27, 2017 ... ... company has entered a settlement agreement to resolve the pending litigation between itself ... Court for the District of Utah). , “I am thrilled to announce that ...
(Date:3/26/2017)... , ... March 26, 2017 , ... ... to receive the RealSelf 100 Award, a prestigious award honoring the top influencers ... and to find and connect with doctors and clinics. , In 2016, more ...
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
(Date:3/24/2017)... ... 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to ... Road. The clinic is the group’s 7th location in San Antonio and 23rd in ... will provide care from the clinic, which opened March 22, 2017. , ...
(Date:3/24/2017)... ... 24, 2017 , ... As the standards bearer of advanced ... that positions them as the go-to thought leader in all matters concerning oncology ... an always-on, always-fresh news, views and advocacy engine, called ONS Voice. , The ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report ... of deep learning solutions within the healthcare domain. Primarily driven by ... novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... 24, 2017  GenomeDx Biosciences today announced that six ... Decipher® Prostate Cancer Classifier tests will be presented at ... (EAU) Congress held March 24 to 28, 2017 in ... Congress is Europe,s largest urological ... the urological field. The abstract titled "Muscle ...
(Date:3/24/2017)... YORK and GENEVA , ... announced on World Tuberculosis Day revitalizes efforts to develop ... On World Tuberculosis Day, TB Alliance and ... for the clinical development of sutezolid, an antibiotic drug ... sublicense pertains to the development of sutezolid in combination ...
Breaking Medicine Technology: